Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
Top Cited Papers
Open Access
- 26 August 2009
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 8 (10), 918-928
- https://doi.org/10.1016/s1474-4422(09)70211-x
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogsAnnals of Neurology, 2009
- In vivo comparison of 2′‐O‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skippingThe Journal of Gene Medicine, 2009
- Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human MuscleHuman Gene Therapy, 2007
- Antisense-mediated exon skipping: A versatile tool with therapeutic and research applicationsRNA, 2007
- Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMDGene Therapy, 2006
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotideThe Journal of Gene Medicine, 2005
- Muscle MRI findings in a three-generation family affected by Bethlem myopathyEuropean Journal of Paediatric Neurology, 2002
- A short protocol for muscle MRI in children with muscular dystrophiesEuropean Journal of Paediatric Neurology, 2002
- Validation of the Hospital Anxiety and Depression Scale for use with adolescentsThe British Journal of Psychiatry, 1999